How do women experience a change in their clinically-derived breast cancer risk estimates: views from a UK Family History Risk and Prevention Clinic

How do women experience a change in their clinically-derived breast cancer risk estimates: views from a UK Family History Risk and Prevention Clinic | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article How do women experience a change in their clinically-derived breast cancer risk estimates: views from a UK Family History Risk and Prevention Clinic Victoria G. Woof, Anthony Howell, Lynne Fox, Lorna McWilliams, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3643438/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 29 Jan, 2026 Read the published version in BMC Cancer → Version 1 posted 10 You are reading this latest preprint version Abstract Background Introducing breast density and polygenic risk scores into breast cancer prediction models results in greater precision and can involve alterations to previously communicated risk estimates and preventative management. This study explored how women from a UK family history risk and prevention clinic view, experience and understand a change in communicated risk. Methods Twenty-two women were interviewed; 11 received an increased risk and 11 a decreased risk. Data were analysed using reflexive thematic analysis. Results Four themes were generated: (i) possibility of change in risk never considered , illustrating women believed their risk estimates would remain unaltered due to their family history, hence receiving a lower risk was shocking but a relief, but an increased risk somewhat unsurprising, (ii) a trusted source influences adapted risk appraisals , highlighting the clinic’s reputation as an information source, as well as personal connections with the service effecting risk appraisals, (iii) perceived value of new risk factor knowledge , where women contemplated the usefulness of knowing their breast density and polygenic risk scores, (iv) heart versus head: changes in preventative management , where the implications of an updated risk estimate was processed. Conclusions Women reacted positively to their updated breast cancer risk estimates and trusted the information provided, even when preventative management options changed. Breast cancer breast cancer risk cancer prevention early detection updated risk estimates qualitative Background In the UK, personalised estimation of breast cancer risk is only provided to those with a strong family history of the disease (e.g. those with affected first or second-degree relatives who meet guidelines for referral [ 1 ]) outside of research settings. Such women may be referred by primary or secondary care for genetic testing and/or to family history risk and prevention clinics (FHRPCs) to determine their lifetime and 10-year risk of developing breast cancer. To calculate breast cancer risk multifactorial risk prediction models, such as Tyrer-Cuzick [ 2 , 3 ] and CanRisk [ 4 ] are used. These models include risk factors such as, family history, body mass index, hormonal and reproductive factors (e.g., age at menarche, hormone replacement therapy (HRT) or oral contraceptive use, age at first full term pregnancy and age of menopause). Diet and health behaviours (i.e. alcohol intake) are also incorporated. Recently, breast cancer risk prediction has become more precise with new strong independent risk factors, breast density (ratio of fibro-glandular tissue to fat in the breast) and a polygenic risk score (PRS; a calculation of genetic variants (single nucleotide polymorphisms (SNPs)) related to hereditary breast cancer) being incorporated into risk prediction models. The inclusion of these risk factors have shown to improve the validity and discriminatory capabilities of the Tyrer-Cuzick [ 5 , 6 , 7 ] and CanRisk [ 8 , 9 , 10 ] models. Consequently, it is likely that these risk factors will be used in clinical settings in the future, as their inclusion would provide more precise risk estimates and treatment stratification [ 11 ]. Presently, women at an above-average (moderate; 5-7.99%) or high (> 8%) 10-year risk of developing breast cancer are offered additional screening up to age 60 years, health behaviour change advice, and preventive medication in line with National Institute of Health and Clinical Excellence (NICE) clinical guidelines [ 1 ]. If updated risk estimates are communicated to those attending FHRPCs, a major challenge will be the inclusion of new risk factors causing changes to previously communicated risk estimates. This could mean that for some, eligibility for early detection and preventative management changes. For example, those who experience a risk reduction may not be eligible for continued annual screening. A recent systematic review of qualitative research [ 12 ] found that clinically-derived breast cancer risk estimates were often not in line with personal risk appraisals. Reasons for this included incongruence between clinical estimates and women’s personal expectations and risk factor misperceptions [ 12 ]. Similarly, a study with women from the general population who received notification of an increased breast cancer risk demonstrated that the nature of personal experiences of breast cancer in others, difficulties attributing breast cancer causes, personal expectations of risk and the perceived usefulness of knowing one’s risk all contributed to how women personally appraised their breast cancer risk, in spite of objective clinical notification [ 13 ]. To date, there appears to be a paucity of research investigating how changes to a personal estimate of disease risk is viewed, understood or experienced for any disease group. As breast cancer risk prediction becomes more precise, it will be essential to understand how women who experience a change in their risk estimates perceive this change and whether new risk information is incorporated into pre-existing breast cancer risk appraisals. This is particularly important if women experience a change in their risk management. The present research addresses this issue by examining views from women taking part in the Family History Risk (FH-Risk) study [ 14 , 15 ] who had the opportunity to receive an updated risk based on all known (to date) risk factors in 2022-23. The aim of the present study therefore was to assess how those who received an update and were notified of a change in their breast cancer risk, view, experience and understand this change. Methods Design Women who attended a consultation (telephone or in-person) with the FHRPC consultant were purposefully sampled from the FH-Risk study. Women were sampled based upon whether they had been notified of a change in their risk (increased or decreased), which may have resulted in a change in NICE clinical guideline categories [ 1 ] and/or changes in early detection or preventative management. Participants and setting Women were sampled from the FH-Risk study [ 14 , 15 ]. These women received a breast cancer risk estimate at first referral to the FHRPC between 1990–2012 and were enrolled in FH-Risk between 2010-12. As part of this study, women received some information on the potential effects of SNP18 (chosen at this time as the panel accounted for around two-thirds of the familial risk component [ 14 ]) on their previously counselled breast cancer risk. This was only an indication that it may have increased if their PRS was above 2.0 or reduced if below 0.5. However, the information received was partially incomplete with the great majority receiving no indication of a change in risk [ 14 , 15 ]. Additionally, although providing consent for the use of their mammogram images, women were not given breast density feedback, as prior to 2013 breast density was not included in risk prediction models. Moderate and high penetrance genes were also not explored in the original study. Women who participated in the FH-Risk study and who were either discharged based on NICE clinical guidelines [ 1 ] or remained under follow-up were given the opportunity (via postal invite) in 2022/23 to be informed of their updated breast cancer risk. If interested, a FHRPC consultant arranged a telephone consultation to discuss this update, with a minority of consultations provided in person when COVID-19 restrictions were lifted. The same consultant provided all risk feedback, with summary letters distributed after each consultation. Summary letters included details of what was discussed and an image to demonstrate women’s breast density. If preventative medication was offered, women also received the appropriate leaflets. To discuss the complexity of SNPs/a PRS the consultant used an analogy in consultations to aid understanding (see supplementary file for summary letter and analogy example). Women who opted to receive their updated breast cancer risk were provided feedback based on the mean risk of the Tyrer-Cuzick [ 2 , 3 ] and CanRisk models [ 4 ], incorporating a PRS (based on a panel of 313 SNPs) [ 9 , 16 ] and breast density (measured using BIRADS™) [ 17 ]. Women also received pathogenic variant feedback on 12 high and moderate penetrance genes linked to breast cancer, including BRCA1/2 [ 18 ]. Incorporating a PRS and breast density into risk prediction models resulted in women’s breast cancer risk increasing, decreasing or staying the same. This meant that for some entitlement for additional screening changed, as well as eligibility for preventative medication. To be eligible for the present study, women needed to have been notified of a change (increase or decrease in risk and/or change in risk category [ 1 ]/early detection and preventative management) in their breast cancer risk and test negative on 12 high and moderate penetrance genes. A negative test for these genes was a requirement as the experiences of receiving positive test results was considered potentially different to those who were non-carriers. Women with a personal breast cancer history were also excluded. Interview procedure Women who received their updated risk feedback were sent a study invite and participant information sheet 1 to 2 months after receiving consultation summary letters. Reminder invite letters were sent 2 to 3 weeks after initial invites. One-to-one telephone or Zoom interviews were arranged with those willing to discuss their updated risk and consultation experience. Prior to interviewing, women provided audio-recorded verbal informed consent. Women were also asked demographic questions (see Table 1 ). A semi-structured flexible topic guide was used throughout the interviews (see supplementary file). As the primary author (VGW) did not have experience of receiving a breast cancer risk, a Patient and Public Involvement and Engagement (PPIE) group comprised of seven women with experience of receiving clinically-derived breast cancer risk estimates helped design the topic guide. This was to ensure that questions related meaningfully to participants. Interviews lasted 28–90 minutes, were recorded, transcribed verbatim by an external agency and pseudonymised. Recruitment ceased when the research team believed there was sufficient data to answer the research question [ 19 ]. Data analysis Data were analysed in NVivo12 using reflexive thematic analysis [ 20 ] approached from a critical realist perspective, meaning authors considered that an external reality exists but can only be partially accessed via subjective sense making. Analysis began with the primary author (VGW; who also conducted the interviews) re-familiarising herself with women’s experiences by reading and re-reading transcripts. First readings took place alongside listening to the corresponding audio recording.. On subsequent re-reads notes were taken of initial ideas and patterns in the transcripts. Following this, initial coding was approached inductively, meaning that codes produced were reflective of the ideas and patterns in the dataset. Deductive analysis was only employed to ensure inductive codes and subsequent themes related meaningfully to the research question. Semantic and latent level coding was used to produce an analysis that represented the experiences communicated by the women, as well as the authors’ interpretations of these experiences. Coding was iterative, with codes refined, re-labelled and collapsed as new data were analysed. Codes were then analysed together and combined to form patterns, which represented meaningful experiences and ideas in the dataset. Initial candidate themes were discussed within the research team and refined until the final thematic structure was established. Results Interview participants Twenty-two women were interviewed, 10 over Zoom and 12 via telephone. Table 1 shows sample demographics and study data. Table 2 indicates changes in 10-year breast cancer risk for each woman. Table 1 Participant demographic and study data Demographics and study data N Age (mean) 47–68 years (56.7 years) Ethnicity White British Jewish American 21 1 Index of Multiple Deprivation decile (mean) 1–10 (6)* Education Postgraduate qualification, i.e. Masters, PhD Degree ‘A’ levels/other post-16 qualifications at college ‘O’ Levels/GCSEs No qualifications 7 5 5 4 1 * higher number meaning living in least deprived areas of the UK [ 21 ] Table 2 Change in 10-year breast cancer risk and management recommendations following the inclusion of a PRS and breast density Participant TC/CR (10Y) mean* TC/CR + PRS & BD (10Y) mean** Previous risk management recommendations Updated risk management recommendations Decreased risk (D) Kerry 8.4 4.55 Annual screening 3-yearly screening Violet 12.5 7 Prescribed preventative medication; annual screening Continue preventative medication; continue annual screening Melissa 5.65 3.15 3-yearly screening Continue 3-yearly screening Alison 6.45 2.7 Annual screening 3-yearly screening Becky 11.5 5.75 3-yearly screening Continue 3-yearly screening Grace 5.5 2.9 Annual screening 3-yearly screening Natalie 7.7 2.3 3-yearly screening Continue 3-yearly screening Tracy 10.75 3.8 Annual screening 3-yearly screening Stef 19.6 6.45 Annual screening Continue annual screening Rose 6.3 2.4 Annual screening 3-yearly screening Leanne 11.4 4.8 Prescribed preventative medication; annual screening Cease preventative medication; 3-yearly screening Increased risk (I) Jenny 5.75 8.5 Annual screening Continue annual screening Alexa 9.8 17.5 Annual screening Consider preventative medication; continue annual screening Hayley 9 12.7 Annual screening Consider preventative medication; continue annual screening Paula 7.45 21.75 3-yearly screening Consider preventative medication; annual screening Pamela 9.45 14.2 3-yearly screening Consider preventative medication; annual screening Harriet 11.05 16.85 Annual screening Consider preventative medication; continue annual screening Lisa 10.75 11.6 3-yearly screening Consider preventative medication; annual screening Abigail 7.35 10.4 Annual screening Consider preventative medication; continue annual screening Bronwen 6.8 9.75 Prescribed preventative medication; annual screening Continue preventive medication; continue annual screening Frances 5.35 6.6 Annual screening Consider preventative medication; continue annual screening Hannah 6.25 14.8 3-yearly screening Consider preventative medication; annual screening *mean 10-year (10Y) risk of the Tyrer-Cuzick (TC) and CanRisk (CR) models , excluding a PRS and breast density (BD), **mean 10-year (10Y) risk of the Tyrer-Cuzick (TC) and CanRisk (CR models , including a PRS and breast density (BD). Reflexive thematic analysis Four themes were generated, (i) possibility of change in risk never considered, (ii) a trusted source influences adapted risk appraisals, (iii) perceived value of new risk factor knowledge and (iv) heart versus head: changes in preventative management. After each pseudonymised quote a ‘D’ or an ‘I’ is used to indicate whether a decrease or an increase in risk was experienced. Possibility of change in risk never considered Only a minority of women had an awareness prior to receiving their updated breast cancer risk that certain risk factors (i.e. health behaviour/diet changes) could affect their estimated risks. Nevertheless, the majority did not seem to possess strong ideas as to whether risk could change, describing never consciously thinking about their risk changing: No, actually I probably didn’t think it would change, no, it didn’t really cross my mind that one, actually… Abigail (I) Most women believed their risk would remain the same throughout their lifetime due to their family history, as they were not aware of any factors that would affect their risk as significantly. When approached by the clinic to receive a more precise risk estimate, it was only at this point where questions about whether risk could change were considered, with women describing feeling curious. Many acknowledged being motivated to seek a risk update due to the impact it could have on their children’s risk, whilst others expressed an interest in hearing about advances in the field. Although having no pre-conceived expectations as to whether their risk had changed, all women described wanting to receive an update in spite of the outcome or implications: …of course I want to know. I want to know whether it’s good or I want to know whether it’s bad. I need to know. So, there was no hesitation in my mind... Lisa (I) Notification of a risk reduction was described as shocking for some. For these women, shock appeared related to the strength of their family history, surprised that their risk could be reduced so dramatically with the inclusion of new risk factors. For Grace, receiving a negative genetic test challenged her expectations and beliefs about her risk, which she had held all her life: …I was expecting to be carrying the gene, and I was expecting to be told that I’m at high-risk, so I was quite shocked when I was told that I wasn’t, and I was low-risk, I wasn’t expecting that at all. Obviously, I was happy about it, but I wasn’t expecting it...Grace (D) Although initially finding a reduced risk a shock, women revealed feeling relieved, with Stef describing it as ‘a weight lifted’ . Conversely, those informed of an increase to their risk were disappointed, but not overly troubled by this news. This is potentially attributable to these women having always ‘lived’ at increased risk of breast cancer, so although risk had increased, this knowledge did not appear to worry them significantly due to the support received from the clinic: I kind of feel reassured and grateful that I know and that I've got this support system in place. But also it’s not, you know, it’s not great news is it, you know, but at least it’s in a context of support, you know […] I was one in four and I've gone to one in three, so it’s not a massively different risk. Hayley (I) Jenny surmised that her risk could potentially change again, indicating her acceptance of the fluidity of risk estimation and her understanding that a clinically-derived breast cancer risk is not definitive: In two years' time they might come across something and say oh, we were wrong, your risk factor is virtually zero […] I think because I know that there could be change, I'm aware that my risk factors could change. Jenny (I) This view was also discussed by others, who argued for regular updates if risk were to change frequently, especially if taking preventative medication or if new risk factors are discovered. Overall, however, women appeared to have little prior concern about their risk consultations and the potential for risk changing. This is likely attributable to women’s long lasting positive relationship with the clinic; identifying confidently that they would feel supported whatever the outcome. A trusted source influences adapted risk appraisal From their initial visit to the FHRPC all women recalled feeling protected by the service and grateful for annual screening. The clinic seemed to provide women with a sense of belonging and community, with consistency of staff, personalised care and a positive atmosphere being highly valued. Attending clinic annually became ‘ routine ’ for some and looked forward to their annual engagement: …I really felt cared for and looked after and part of a family [at the FHRPC], because as I say, I’ve always trusted [name of clinician], the people I’ve met there, you know? I’ve always felt that they had my best interests at heart. Becky (D) With this in mind, when receiving their updated breast cancer risk estimates women appeared positive and trusted the new estimate provided. Women’s trust in the service and the value attributed to it also seemed to influence the ease in which new risk estimates were internalised and accepted. Integration of new risk factors, breast density and a PRS seemed to be accomplished with relative ease, accepting the clinician’s knowledge and re-defining personal risk appraisals in line with this information: …the things that really stuck with me that we talked about were…that I didn't have any of the genetic markers [high-penetrance genes], but they looked at 300 markers [SNPs] on my DNA, and that's where I had the higher risk, that’s where the higher risk came from. Harriet (I) The majority of women described their risk as changed and attributed changes to breast density and a PRS, as well as results informing them of their non-carrier status for pathogenic variants in 12 high-penetrance breast cancer genes. Following communication of this information there appeared to be a shift in the majority of women’s understandings of their risk from their initial FHRPC visit, where a family history and the assumption of being a gene mutation carrier were considered the key drivers in their risk. Following their updated risk notification, women described appreciating the impact of these new risk factors, whilst also processing past assumptions about their genetic risk: I had probably assumed and probably wrongly before I knew that there wasn’t a genetic link. What I hadn’t appreciated was some of the other factors still added up to the higher than average risk […] So again, let’s say I was surprised. I wasn’t particularly upset, but I was maybe surprised. But that’s always because I’d worked on an assumption...Bronwen (I) Following notification of their updated risk, women openly discussed understanding that low or high breast density, or, a low or high PRS resulted in risk reducing or increasing. Women described understanding the ‘take home message’ of this information and felt they had sufficient knowledge to enable them to integrate this information into an improved understanding of risk: …he explained to me about how my breast density had changed since I started on the programme years ago and they’d become much more denser and now I was in the most dense category, and that obviously increased my risk...Alexa (I) Developing a ‘gist’ understanding may have been facilitated by how both a PRS and breast density were communicated. Specifically, an analogy provided to explain a PRS/SNPs, as well as a visual representation of breast density was described as helpful in enabling women to understand the contribution of these factors to their updated risk. These techniques and positive relationships with the clinic appeared to result in most personal risk appraisals being in line with the updated estimate provided. Perceived value of new risk factor knowledge All women mentioned breast density, a PRS and their non-carrier status for pathogenic variants when describing their change in risk. Non-carrier status for pathogenic variants in high-penetrance genes seemed to be particularly significant, with women elated by their result, not only for themselves but for their children. For some this information and a PRS was considered simultaneously. By doing so, attention attributed to their PRS appeared reduced, due to the overwhelming affective response associated with their non-carrier status. Instead, women appeared to possess a vague but mostly accurate understanding of their PRS and its contribution to their risk, and seemed satisfied with this level of knowledge. When considering the usefulness of knowing their PRS, some explained the futility of dwelling on the score, due to their inability to control it: I can only manage the factors that I can manage […] The fact that they’re [SNPs] there, I can’t change them, so I’m not going to overly worry about it. Bronwen (I) Breast density results were considered in more depth. Prior to receiving their update, some women had a vague understanding of breast density, however most explanations comprised of inaccurate knowledge or misunderstandings. Accuracy of knowledge remained mixed after receiving an updated risk estimate. Women instead focused on the overall contribution of their breast density to their risk and as with knowledge for SNPs/a PRS, appeared satisfied with ‘gist’ knowledge: As small as they are [her breasts], you know, they are made of matter that is not great in terms of breast cancer. You know, that’s how I read it, that’s how I feel about it...Lisa (I) Most women acknowledged the usefulness of knowing their breast density, with some considering or pursuing preventative medication to reduce it. Communication of breast density was also considered important more widely, with women advocating that all eligible woman should be given the opportunity to know their breast density. However, women identified some caveats to breast density communication. Specifically, they questioned the usefulness of breast density information if nothing conclusive can be done to manage it. Additionally, the usefulness of providing breast density information in isolation of other known risk factors was also considered. Heart versus head: changes in preventative management For some women still under follow-up at the FHRPC, their updated risk estimates resulted in them being ineligible for annual screening. This was due to their risk reducing below the level recommended for additional screening in NICE guidelines. This appeared to cause conflict emotionally, with women understanding they were no longer eligible and accepting this, yet feeling a sense of loss from being discharged. Despite being pleased that risk had reduced, losing the protectiveness and comfort the service offers was challenging to reconcile: …when he said I’d go to the three [yearly screening], that’s just the bit that made me think a bit. And I’ve not got to think like that but it’s just made me think, oh, crikey, yeah, a bit, makes me a bit more nervous now of it [breast cancer] again, but then I shouldn’t do, I’ve got to think of the positives. Leanne (D) Some appeared dubious about population screening and attending 3-yearly. Although trusting their updated risk and the clinician’s recommendations to attend for 3-yearly screening, women were apprehensive about the level of service they would encounter, as well as whether staff would be aware of their FHRPC involvement. For these women, 3-yearly screening would be a difficult transition despite understanding why they were no longer eligible. These concerns aligned with those who had previously been discharged from the clinic at age 60, who criticised population screening for being impersonal, with some not trusting negative mammogram results: I’m just going to be a number to them whereas I’m a name to [name of clinician] […] I walk into the one there and they don’t know my name, they don’t know me from Adam or Eve, they take longer to get the results back to you. It’s only every three years. Nobody ever discusses anything with you […] there’s no connection. Becky (D) In contrast, women in follow-up notified of a risk increase described experiencing a sense of relief due to remaining eligible for annual screening. Additionally, those who had been discharged and notified that their updated risk entitled them to receive annual screening were elated to be back in the FHRPC. For these women an increased risk was of course concerning, but this update seemed to act as an ‘entrance ticket’ or gateway back into the FHRPC. These women appeared to focus more on the positivity of additional surveillance, rather than the implications of the risk itself: It’s a double-edged sword, isn’t it? Your risk has gone higher, but guess what, you’re going to have it [mammography] once a year, yay. No, I’m actually quite happy about that, and I’m relieved, because if my risk level has gone up, obviously I then want as much preventative help, if you like, as possible, so I’m well happy to come once a year…Paula (I) Three women at the time of interviewing were taking preventative medication, with one woman, Leanne, advised to discontinue as a result of her updated risk. Leanne described feeling encouraged that taking preventative medication had appeared to reduce her risk and was positive about the prospect of being able to take a natural form of HRT to reduce her menopausal symptoms. Other women considered the thought of being asked to discontinue preventative medication hypothetically, with many explaining that although potentially worrying, medication was prescribed with the correct knowledge available at the time and not due to inaccurate information or medical negligence. Other women who had been offered preventative medication described it as ‘a no brainer’ (Hayley, I) if it reduces risk but were cautious about side-effects, describing trusting the advice of the clinician but also needing to weigh up the ratio of harms to benefits before use. Discussion Women who experienced a change in their clinically-derived breast cancer risk estimate reacted positively and trusted the estimate provided. A reduction in risk was met with relief as well as surprise, due to the previously perceived impact of family history on risk compared to other risk factors. Those who experienced a risk increase were not overly concerned by this, possibly due to seeing themselves as being at increased risk for most of their lives. Women described having a longstanding positive relationship with the FHRPC which appeared to influence the trust they had in their updated risk, as well as influencing the apparent ease at which they were able to integrate new risk information into pre-existing risk appraisals. A ‘gist’ understanding of new risk information seemed to be sufficient in enabling women to understand the ‘take home message’ of their breast cancer risk. Finally, for those at increases risk, updated estimates enable those under follow-up to remain so and facilitated a pathway back into the service for those previously discharged, resulting in positive reactions to this risk level. However, ineligibility for continued annual screening for those at reduced risk was difficult to reconcile. Relevance to existing literature Women who were informed that their risk had increased accepted this news and did not appear overly concerned, nor did those referred back into the clinic blame the service for being discharged previously. Instead women here focused on their eligibility for annual screening and the elation of being referred back into the clinic. This contrasts with research suggesting that those given information about an increased risk or negative health outcome question the accuracy of the results and credibility of the source [ 22 ]. It is widely established that in the UK, cancer screening is highly valued [ 23 ]. Specifically, women living at chronic risk of breast and ovarian cancer view frequent screening as providing peace of mind and a sense of control [ 24 ]. Additionally, prior to diagnosis, those with breast cancer recalled having confidence in mammography, the clinic and their care [ 25 ]. In the present study the positivity of qualifying for more frequent screening outweighed the implications of a change in risk. This is in line with research that suggests although clinical risk consultations may contain messages of uncertainty and notifications of an increased risk, women tend to focus on the reassurance of the appointment and being a part of a ‘surveillance’ society [ 26 ]. Women’s appraisals of their breast cancer risk following their update were mostly in line with the clinical estimate provided. Women were able, with confidence, to attribute risk changes to their personal breast density, PRS or a combination, acknowledging the implications of these new risk factors. These findings are in contrast to those found with women from the general screening population who also received similar feedback where some women did not identify with their risk estimates, nor did they draw on specific risk factors to explain their risk [ 13 ]. However, there were significant differences in how risk was communicated in these two studies. For women in the general population, notification was received via letter, with a minority attending a consultation. Instead, established relationships with the clinic in the present study, as well as the ‘routine’ of discussing breast cancer risk may have influenced how open women were to receiving new risk information. This positive relationship with the FHRPC also seemed to positively impact women’s trust in the updated risk estimate provided, as well as influencing views on its credibility. It may also account for why those discharged felt apprehensive when faced with population screening, as relationships built at the FHRPC and comfort received would cease. This apprehension is also found in women offered risk estimation and stratification in the general population, with those previously receiving annual screening questioning the safety of 3-yearly screening and feeling less in control of their risk [ 27 ]. Implications for practice Women who were informed that their updated breast cancer risk estimate caused them to be ineligible for additional breast screening felt a sense of loss and were wary about population screening. In FHRPCs communication needs to be carefully managed when women are discharged, with reasons thoroughly explained and concerns surrounding the perceived competence of population breast screening alleviated. Specifically, FHRPCs should reinforce that staff (i.e. radiographers and radiologists) at population screening require the same level of training as those performing mammograms at FHRPCs. At population screening, radiographers should be made aware of women’s involvement in FHRPCs. Possessing this knowledge and demonstrating this to those recently discharged would perhaps reduce apprehensions and create a more personalised environment, making this transition easier. It is understood that ‘gist’ health messages can increase patient satisfaction and are important for facilitating understanding and informed decision making around health risks [ 28 , 29 ]. Understanding the ‘gist’ of their updated risk was sufficient for women to appreciate the most salient information from their consultations, resulting in mostly accurate risk appraisals and an appreciation of the impact of new risk factors. It has been recommended that risk communication research should move away from assessing patient’s verbatim representations of risk information and instead assess ‘gist’ representations, asking the question, ‘what does this risk information mean to the individual? ’ [ 29 ]. In clinical settings this level of understanding should be facilitated to enable patients to gain sufficient knowledge to inform ‘accurate’ personal appraisals of their risk and aid informed decision making. The use of visuals (e.g. breast density images) and analogies (e.g. like that given to explain SNPs/a PRS in the present study; see supplementary file) appear to be an effective way of facilitating this [ 30 ]. Women in the present study advocated for breast density notification for all. In the UK notification of personal breast density is only provided in research settings. Research from the US advises that education materials and breast density communication in clinical settings needs to be specifically addressed in order to help women make informed decisions about prevention management [ 31 ]. Measures of breast density need to be agreed upon and prevention advice clear in the UK before communicating at a population level [ 32 ]. In the present study a PRS/SNPs information was attended to less than breast density, with a negative pathogenic variant test for high penetrance genes overshadowing the implications of a PRS. Healthcare professionals should consider providing written summaries of the implications of a PRS, or direct patients to a website to help facilitate knowledge acquisition once the affective response of receiving negative genetic test results subsides. Strengths and limitations This is the first research study for any disease type to explore how a change in personal risk is understood, and reacted to in a clinical setting. It is important however to be cognisant that women interviewed were predominantly White-British, from one FHRPC and were seen by the same clinician employed at the clinic for the duration of women’s involvement with the service. Therefore, the relationship these women have with the clinic, which has been described as a ‘centre for excellence’, may not be representative of patient-clinician relationships in other FHRPCs or clinical settings worldwide, although it clearly shows that it is possible for patients to receive revised risk estimates without major adverse reactions. Findings in qualitative data analysis are at least partly a result of the subjectivity of the researchers generating and analysing the data [ 20 ]. The research team contributing to this work are from a range of disciplinary backgrounds, including health psychology, medical oncology and clinical genetics. The multi-disciplinary nature of this team resulted in meaningful discussions about the data, providing different perspectives on the themes generated. Prior to data generation, the research team had pre-existing apprehensions regarding reactions to a change in risk, especially if related to a change in preventative management. Although these concerns did not materialise, pre-conceived ideas were discussed openly prior to the interviews. Further research Future research should establish how relationships between patients and doctors impact the effectiveness of risk communication and the trust patients have in updated risk estimates across different disease types and clinical settings. As well, research aiming to assess breast cancer risk appraisals across the entire FH-Risk cohort would be beneficial. This would facilitate an understanding as to whether risk appraisals are in line with the clinical estimates provided overall, as well as enable opportunities to explore how women view a changes in risk, as well as whether they have an understanding of the contributing risk factors. The longevity of ‘gist’ understandings and the impact this has on patient’s appraisals of a given disease risk and their informed decision making about prevention should also be assessed. Conclusion Women were positive about receiving a notification of change in breast cancer risk and trusted the estimate provided. This may have been due to a strong trust in the service communicating these updated risk estimates, facilitating an accurate appraisal of risk which was mostly in line with the clinical estimate provided. Abbreviations FH-Risk – Family history risk study FHRPC – Family history risk and prevention clinic HRT – Hormone replacement therapy NICE – National institute for health and care excellence PPIE – Patient and public involvement and engagement PRS – Polygenic risk score SNPs – Single nucleotide polymorphisms Declarations Ethics approval and consent to participate Ethical approval was granted by HSC REC A ethics committee (ref: 21/NI/0130). All women provided verbal informed consent that was audio-recorded. Consent for publication Consent to publish anonymised data, including direct quotes was obtained from all the women who took part in the present study. Availability of data and materials The datasets generated during and/or analysed during the current study are not publicly available as they may contain information that would compromise participant consent, but are available from the corresponding author on reasonable request. Competing interests The authors declare that they have no conflict of interest. Funding The original FH-Risk study was funded by an NIHR Programme Grant for Applied Research (RP-PG-0707-10031). The present work was supported by a Medical Research Council PhD studentship for the primary author (MR/N013751/1). This work was also supported by the NIHR Manchester Biomedical Research Centre Cancer Prevention and Early Detection theme (IS-BRC-1215-20007 and NIHR203308). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. These funding sources had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results. Authors' contributions The concept of the study was designed by all authors. Recruitment was carried out by VGW and LF. Data were collected by VGW. Primary data analysis was conducted by VGW and supervised by DPF. VGW wrote the manuscript. The final manuscript was reviewed, edited and approved by all the authors. Acknowledgements We would like to acknowledge the wider team at the FHRPC, as well as those in the research office. We would also like to thank the Patient and Public Involvement Group as well as those at VOCAL who helped develop the topic guide for this study. Finally, we would like to extend a special thanks to all the women who took part for their continued dedication to the FH-Risk studies. References National Institute of Health and Clinical Excellence. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. NICE clinical guideline 164., 2013; 2019. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111–30. Tyrer-Cuzick (IBIS). Risk Evaluation Tool, Version 8. Retrieved from https://ems-trials.org/riskevaluator/ (accessed June 2023). Carver, T., Hartley, S., Lee, A., Cunningham, A. P., Archer, S., Babb de Villiers,C., … Antoniou, A. C. (2021). CanRisk Tool—A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants.Cancer Epidemiology, Biomarkers & Prevention, 30(3), 469–473. Brentnall AR, Cohn WF, Knaus WA, Yaffe MJ, Cuzick J, Harvey JA. A case-control study to add volumetric or clinical mammographic density into the Tyrer-Cuzick breast cancer risk model. J breast imaging. 2019;1(2):99–106. Brentnall, A. R., van Veen, E. M., Harkness, E. F., Rafiq, S., Byers, H., Astley,S. M., … Evans, D. G. R. (2020). A case–control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. International journal of cancer, 146(8), 2122–2129. Evans, D. G. R., van Veen, E. M., Harkness, E. F., Brentnall, A. R., Astley, S. M.,Byers, H., … Howell, A. (2022). Breast cancer risk stratification in women of screening age: incremental effects of adding mammographic density, polygenic risk, and a gene panel. Genetics in Medicine, 24(7), 1485–1494. Lee, A., Mavaddat, N., Wilcox, A. N., Cunningham, A. P., Carver, T., Hartley, S.,… Antoniou, A. C. (2019). BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genetics in Medicine, 21(8),1708–1718. Pal Choudhury, P., Brook, M. N., Hurson, A. N., Lee, A., Mulder, C. V., Coulson, P.,… Garcia-Closas, M. (2021). Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. Breast Cancer Research, 23, 1–5. Ficorella, L., Eriksson, M., Czene, K., Leslie, G., Yang, X., Carver, T. J., … Antoniou,A. C. (2023). Incorporating continuous mammographic density into the BOADICEA breast cancer risk prediction model. Cancer Research, 83(7_Supplement), 4174–4174. Howell, A., Gandhi, A., Howell, S., Wilson, M., Maxwell, A., Astley, S., … Evans,D. G. (2020). Long-term evaluation of women referred to a breast cancer family history clinic (Manchester UK 1987–2020). Cancers, 12(12), 3697. Woof VG, Howell A, McWilliams L, Evans DG, French DP. (2022). How do women who are informed that they are at increased risk of breast cancer appraise their risk? A systematic review of qualitative research. Br J Cancer, 1–9. Woof VG, McWilliams L, Howell A, Evans DG, French DP. How do women at increased risk of breast cancer make sense of their risk? An interpretative phenomenological analysis. Br J Health Psychol. 2023;00:1–16. Evans, D. G., Brentnall, A., Byers, H., Harkness, E., Stavrinos, P., Howell, A., …FH-risk study Group. (2017). The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case–control study. Journal of medical genetics, 54(2), 111–113. Evans, D. G., Astley, S., Stavrinos, P., Harkness, E., Donnelly, L. S., Dawe, S.,… Howell, A. (2016). Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics:a dual cohort study. NIHR Journals Library, Southampton (UK); PMID: 27559559. Mavaddat, N., Michailidou, K., Dennis, J., Lush, M., Fachal, L., Lee, A., … MacInnis,R. J. (2019). Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. The American Journal of Human Genetics, 104(1), 21–34. Balleyguier C, Ayadi S, Van Nguyen K, Vanel D, Dromain C, Sigal R. BIRADS™ classification in mammography. Eur J Radiol. 2007;61(2):192–4. Breast Cancer Association Consortium. Breast cancer risk genes—association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428–39. O’reilly M, Parker N. Unsatisfactory Saturation’: a critical exploration of the notion of saturated sample sizes in qualitative research. Qualitative Res. 2013;13(2):190–7. Braun V, Clarke V. Reflecting on reflexive thematic analysis. Qualitative Res sport Exerc health. 2019;11(4):589–97. Ministry of Housing, Communities, Local Government. English indices of deprivation 2019. [Online] 2019 [Accessed 1st September 2023]. Available from: https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019 . Panzer M, Renner B. To be or not to be at risk: Spontaneous reactions to risk information. Psychol Health. 2008;23(5):617–27. Waller J, Osborne K, Wardle J. Enthusiasm for cancer screening in Great Britain: a general population survey. Br J Cancer. 2015;112(3):562–6. Kenen R, Ardern-Jones A, Eeles R. Living with chronic risk: healthy women with a family history of breast/ovarian cancer. Health Risk & Society. 2003;5(3):315–31. Clements, A., Henderson, B. J., Tyndel, S., Evans, G., Brain, K., Austoker, J., …PIMMS Study Management Group. (2008). Diagnosed with breast cancer while on a family history screening programme: an exploratory qualitative study. European journal of cancer care, 17(3), 245–252. Parsons EP, Beale V, Bennett H, Jones J, Lycett EJ. Reassurance through surveillance in the face of clinical uncertainty: the experience of women at risk of familial breast cancer. Health Expect. 2000;3(4):263–73. McWilliams L, Ruane H, Ulph F, Woof VG, Harrison F, Evans DG, French DP. (2023). What do women think about having received their breast cancer risk as part of a risk-stratified NHS Breast Screening Programme? A qualitative study. Br J Cancer, 1–10. Reyna VF. A theory of medical decision making and health: fuzzy trace theory. Med Decis Making. 2008;28(6):850–65. Blalock SJ, DeVellis RF, Chewning B, Sleath BL, Reyna VF. Gist and verbatim communication concerning medication risks/benefits. Patient Educ Couns. 2016;99(6):988–94. Wilhelms EA, Reyna VF. Effective ways to communicate risk and benefit. The virtual mentor: VM. 2013;15(1):34. Schifferdecker, K. E., Tosteson, A. N., Kaplan, C., Kerlikowske, K., Buist, D. S.,Henderson, L. M., … Wernli, K. J. (2020). Knowledge and perception of breast density,screening mammography, and supplemental screening: in search of “informed”. Journal of general internal medicine, 35, 1654–1660. Duffy, S. W., Morrish, O. W., Allgood, P. C., Black, R., Gillan, M. G., Willsher,P., … Maroni, R. (2018). Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer. European Journal of Cancer, 88, 48–56. Additional Declarations No competing interests reported. Supplementary Files WoofetalFHRisk2.0COREQChecklistBMCC16.11.23.pdf WoofetalFHRisk2.0SuppFileBMCC16.11.2023.docx Cite Share Download PDF Status: Published Journal Publication published 29 Jan, 2026 Read the published version in BMC Cancer → Version 1 posted Editorial decision: Revision requested 23 Oct, 2024 Reviews received at journal 07 Sep, 2024 Reviews received at journal 06 Sep, 2024 Reviewers agreed at journal 28 Aug, 2024 Reviewers agreed at journal 28 Aug, 2024 Reviewers invited by journal 11 Dec, 2023 Editor assigned by journal 11 Dec, 2023 Editor invited by journal 30 Nov, 2023 Submission checks completed at journal 30 Nov, 2023 First submitted to journal 21 Nov, 2023 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3643438","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":330066413,"identity":"17b0c19f-0404-4ddd-8996-4ff8ecf79e9f","order_by":0,"name":"Victoria G. Woof","email":"data:image/png;base64,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","orcid":"","institution":"University of Manchester","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Victoria","middleName":"G.","lastName":"Woof","suffix":""},{"id":330066414,"identity":"44890b92-552d-490a-a869-af28ad72fefe","order_by":1,"name":"Anthony Howell","email":"","orcid":"","institution":"University of Manchester","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Anthony","middleName":"","lastName":"Howell","suffix":""},{"id":330066415,"identity":"8d45034c-2549-4381-825c-affe89f2ae5d","order_by":2,"name":"Lynne Fox","email":"","orcid":"","institution":"Manchester University NHS Foundation Trust","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Lynne","middleName":"","lastName":"Fox","suffix":""},{"id":330066416,"identity":"90dfe459-949b-451c-8efa-23a6762ac059","order_by":3,"name":"Lorna McWilliams","email":"","orcid":"","institution":"University of Manchester","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Lorna","middleName":"","lastName":"McWilliams","suffix":""},{"id":330066417,"identity":"03293c7a-8359-4ef6-9b32-a6331dac72f5","order_by":4,"name":"D Gareth Evans","email":"","orcid":"","institution":"University of Manchester","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"D","middleName":"Gareth","lastName":"Evans","suffix":""},{"id":330066418,"identity":"385d4d76-1795-4ca5-9b75-285257cecaa8","order_by":5,"name":"David P French","email":"","orcid":"","institution":"University of Manchester","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"David","middleName":"P","lastName":"French","suffix":""}],"badges":[],"createdAt":"2023-11-21 10:14:25","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3643438/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3643438/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12885-026-15651-w","type":"published","date":"2026-01-29T15:59:22+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":101691167,"identity":"e8ba03ee-ab72-4f35-926a-3c415b3f0f53","added_by":"auto","created_at":"2026-02-02 16:12:46","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":940246,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3643438/v1/417bd03a-57e1-4861-a80b-2acf9f83c234.pdf"},{"id":61670327,"identity":"0d78e6b6-3414-44e1-9e09-1f6ea17b84d6","added_by":"auto","created_at":"2024-08-02 18:05:57","extension":"pdf","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":493563,"visible":true,"origin":"","legend":"","description":"","filename":"WoofetalFHRisk2.0COREQChecklistBMCC16.11.23.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3643438/v1/a2d77633a9ac57607a54a395.pdf"},{"id":61670326,"identity":"9ff25d68-07e6-4c96-90ae-9cdfaf1f49e6","added_by":"auto","created_at":"2024-08-02 18:05:57","extension":"docx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":114756,"visible":true,"origin":"","legend":"","description":"","filename":"WoofetalFHRisk2.0SuppFileBMCC16.11.2023.docx","url":"https://assets-eu.researchsquare.com/files/rs-3643438/v1/8925f08469efc9b9603d7d44.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"How do women experience a change in their clinically-derived breast cancer risk estimates: views from a UK Family History Risk and Prevention Clinic","fulltext":[{"header":"Background","content":"\u003cp\u003eIn the UK, personalised estimation of breast cancer risk is only provided to those with a strong family history of the disease (e.g. those with affected first or second-degree relatives who meet guidelines for referral [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]) outside of research settings. Such women may be referred by primary or secondary care for genetic testing and/or to family history risk and prevention clinics (FHRPCs) to determine their lifetime and 10-year risk of developing breast cancer.\u003c/p\u003e \u003cp\u003eTo calculate breast cancer risk multifactorial risk prediction models, such as Tyrer-Cuzick [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e] and CanRisk [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e] are used. These models include risk factors such as, family history, body mass index, hormonal and reproductive factors (e.g., age at menarche, hormone replacement therapy (HRT) or oral contraceptive use, age at first full term pregnancy and age of menopause). Diet and health behaviours (i.e. alcohol intake) are also incorporated. Recently, breast cancer risk prediction has become more precise with new strong independent risk factors, breast density (ratio of fibro-glandular tissue to fat in the breast) and a polygenic risk score (PRS; a calculation of genetic variants (single nucleotide polymorphisms (SNPs)) related to hereditary breast cancer) being incorporated into risk prediction models. The inclusion of these risk factors have shown to improve the validity and discriminatory capabilities of the Tyrer-Cuzick [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e] and CanRisk [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e] models. Consequently, it is likely that these risk factors will be used in clinical settings in the future, as their inclusion would provide more precise risk estimates and treatment stratification [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e].\u003c/p\u003e \u003cp\u003ePresently, women at an above-average (moderate; 5-7.99%) or high (\u0026gt;\u0026thinsp;8%) 10-year risk of developing breast cancer are offered additional screening up to age 60 years, health behaviour change advice, and preventive medication in line with National Institute of Health and Clinical Excellence (NICE) clinical guidelines [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. If updated risk estimates are communicated to those attending FHRPCs, a major challenge will be the inclusion of new risk factors causing changes to previously communicated risk estimates. This could mean that for some, eligibility for early detection and preventative management changes. For example, those who experience a risk reduction may not be eligible for continued annual screening.\u003c/p\u003e \u003cp\u003eA recent systematic review of qualitative research [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e] found that clinically-derived breast cancer risk estimates were often not in line with personal risk appraisals. Reasons for this included incongruence between clinical estimates and women\u0026rsquo;s personal expectations and risk factor misperceptions [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Similarly, a study with women from the general population who received notification of an increased breast cancer risk demonstrated that the nature of personal experiences of breast cancer in others, difficulties attributing breast cancer causes, personal expectations of risk and the perceived usefulness of knowing one\u0026rsquo;s risk all contributed to how women personally appraised their breast cancer risk, in spite of \u003cem\u003eobjective\u003c/em\u003e clinical notification [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eTo date, there appears to be a paucity of research investigating how changes to a personal estimate of disease risk is viewed, understood or experienced for any disease group. As breast cancer risk prediction becomes more precise, it will be essential to understand how women who experience a change in their risk estimates perceive this change and whether new risk information is incorporated into pre-existing breast cancer risk appraisals. This is particularly important if women experience a change in their risk management. The present research addresses this issue by examining views from women taking part in the Family History Risk (FH-Risk) study [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e] who had the opportunity to receive an updated risk based on all known (to date) risk factors in 2022-23. The aim of the present study therefore was to assess how those who received an update and were notified of a change in their breast cancer risk, view, experience and understand this change.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eDesign\u003c/h2\u003e \u003cp\u003eWomen who attended a consultation (telephone or in-person) with the FHRPC consultant were purposefully sampled from the FH-Risk study. Women were sampled based upon whether they had been notified of a change in their risk (increased or decreased), which may have resulted in a change in NICE clinical guideline categories [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e] and/or changes in early detection or preventative management.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eParticipants and setting\u003c/h2\u003e \u003cp\u003eWomen were sampled from the FH-Risk study [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. These women received a breast cancer risk estimate at first referral to the FHRPC between 1990\u0026ndash;2012 and were enrolled in FH-Risk between 2010-12. As part of this study, women received some information on the potential effects of SNP18 (chosen at this time as the panel accounted for around two-thirds of the familial risk component [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]) on their previously counselled breast cancer risk. This was only an indication that it may have increased if their PRS was above 2.0 or reduced if below 0.5. However, the information received was partially incomplete with the great majority receiving no indication of a change in risk [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Additionally, although providing consent for the use of their mammogram images, women were not given breast density feedback, as prior to 2013 breast density was not included in risk prediction models. Moderate and high penetrance genes were also not explored in the original study.\u003c/p\u003e \u003cp\u003eWomen who participated in the FH-Risk study and who were either discharged based on NICE clinical guidelines [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e] or remained under follow-up were given the opportunity (via postal invite) in 2022/23 to be informed of their updated breast cancer risk. If interested, a FHRPC consultant arranged a telephone consultation to discuss this update, with a minority of consultations provided in person when COVID-19 restrictions were lifted. The same consultant provided all risk feedback, with summary letters distributed after each consultation. Summary letters included details of what was discussed and an image to demonstrate women\u0026rsquo;s breast density. If preventative medication was offered, women also received the appropriate leaflets. To discuss the complexity of SNPs/a PRS the consultant used an analogy in consultations to aid understanding (see supplementary file for summary letter and analogy example).\u003c/p\u003e \u003cp\u003eWomen who opted to receive their updated breast cancer risk were provided feedback based on the mean risk of the Tyrer-Cuzick [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e] and CanRisk models [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e], incorporating a PRS (based on a panel of 313 SNPs) [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e] and breast density (measured using BIRADS\u0026trade;) [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. Women also received pathogenic variant feedback on 12 high and moderate penetrance genes linked to breast cancer, including \u003cem\u003eBRCA1/2\u003c/em\u003e [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. Incorporating a PRS and breast density into risk prediction models resulted in women\u0026rsquo;s breast cancer risk increasing, decreasing or staying the same. This meant that for some entitlement for additional screening changed, as well as eligibility for preventative medication.\u003c/p\u003e \u003cp\u003eTo be eligible for the present study, women needed to have been notified of a change (increase or decrease in risk and/or change in risk category [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]/early detection and preventative management) in their breast cancer risk and test negative on 12 high and moderate penetrance genes. A negative test for these genes was a requirement as the experiences of receiving positive test results was considered potentially different to those who were non-carriers. Women with a personal breast cancer history were also excluded.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eInterview procedure\u003c/h2\u003e \u003cp\u003e Women who received their updated risk feedback were sent a study invite and participant information sheet 1 to 2 months after receiving consultation summary letters. Reminder invite letters were sent 2 to 3 weeks after initial invites. One-to-one telephone or Zoom interviews were arranged with those willing to discuss their updated risk and consultation experience. Prior to interviewing, women provided audio-recorded verbal informed consent. Women were also asked demographic questions (see Table \u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). A semi-structured flexible topic guide was used throughout the interviews (see supplementary file). As the primary author (VGW) did not have experience of receiving a breast cancer risk, a Patient and Public Involvement and Engagement (PPIE) group comprised of seven women with experience of receiving clinically-derived breast cancer risk estimates helped design the topic guide. This was to ensure that questions related meaningfully to participants. Interviews lasted 28\u0026ndash;90 minutes, were recorded, transcribed verbatim by an external agency and pseudonymised. Recruitment ceased when the research team believed there was sufficient data to answer the research question [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eData analysis\u003c/h2\u003e \u003cp\u003eData were analysed in NVivo12 using reflexive thematic analysis [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e] approached from a critical realist perspective, meaning authors considered that an external reality exists but can only be partially accessed via subjective sense making. Analysis began with the primary author (VGW; who also conducted the interviews) re-familiarising herself with women\u0026rsquo;s experiences by reading and re-reading transcripts. First readings took place alongside listening to the corresponding audio recording.. On subsequent re-reads notes were taken of initial ideas and patterns in the transcripts. Following this, initial coding was approached inductively, meaning that codes produced were reflective of the ideas and patterns in the dataset. Deductive analysis was only employed to ensure inductive codes and subsequent themes related meaningfully to the research question. Semantic and latent level coding was used to produce an analysis that represented the experiences communicated by the women, as well as the authors\u0026rsquo; interpretations of these experiences. Coding was iterative, with codes refined, re-labelled and collapsed as new data were analysed. Codes were then analysed together and combined to form patterns, which represented meaningful experiences and ideas in the dataset. Initial candidate themes were discussed within the research team and refined until the final thematic structure was established.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eInterview participants\u003c/h2\u003e \u003cp\u003eTwenty-two women were interviewed, 10 over Zoom and 12 via telephone. Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e shows sample demographics and study data. Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e indicates changes in 10-year breast cancer risk for each woman.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eParticipant demographic and study data\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDemographics and study data\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge (mean)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e47\u0026ndash;68 years (56.7 years)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEthnicity\u003c/p\u003e \u003cp\u003e\u003cem\u003eWhite British\u003c/em\u003e\u003c/p\u003e \u003cp\u003e\u003cem\u003eJewish American\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e21\u003c/p\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIndex of Multiple Deprivation decile (mean)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u0026ndash;10 (6)*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEducation\u003c/p\u003e \u003cp\u003e\u003cem\u003ePostgraduate qualification, i.e. Masters, PhD\u003c/em\u003e\u003c/p\u003e \u003cp\u003e\u003cem\u003eDegree\u003c/em\u003e\u003c/p\u003e \u003cp\u003e\u003cem\u003e\u0026lsquo;A\u0026rsquo; levels/other post-16 qualifications at college\u003c/em\u003e\u003c/p\u003e \u003cp\u003e\u003cem\u003e\u0026lsquo;O\u0026rsquo; Levels/GCSEs\u003c/em\u003e\u003c/p\u003e \u003cp\u003e\u003cem\u003eNo qualifications\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7\u003c/p\u003e \u003cp\u003e5\u003c/p\u003e \u003cp\u003e5\u003c/p\u003e \u003cp\u003e4\u003c/p\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"2\"\u003e\u003cb\u003e*\u003c/b\u003e\u003cem\u003ehigher number meaning living in least deprived areas of the UK\u003c/em\u003e [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eChange in 10-year breast cancer risk and management recommendations following the inclusion of a PRS and breast density\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eParticipant\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTC/CR (10Y) mean*\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eTC/CR\u0026thinsp;+\u0026thinsp;PRS \u0026amp; BD (10Y) mean**\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePrevious risk management recommendations\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eUpdated risk management recommendations\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eDecreased risk (D)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eKerry\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnnual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eViolet\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e12.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePrescribed preventative medication; annual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eContinue preventative medication; continue annual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMelissa\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3.15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eContinue\u003c/p\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlison\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6.45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnnual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBecky\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eContinue\u003c/p\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGrace\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnnual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNatalie\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eContinue\u003c/p\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTracy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnnual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStef\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e19.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6.45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnnual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eContinue\u003c/p\u003e \u003cp\u003eannual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRose\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnnual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLeanne\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePrescribed preventative medication; annual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eCease preventative medication; 3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eIncreased risk (I)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eJenny\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnnual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eContinue\u003c/p\u003e \u003cp\u003eannual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlexa\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e17.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnnual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eConsider preventative medication; continue annual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHayley\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnnual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eConsider preventative medication; continue annual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePaula\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7.45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eConsider preventative medication; annual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePamela\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9.45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eConsider preventative medication; annual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHarriet\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11.05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16.85\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnnual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eConsider preventative medication; continue annual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLisa\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e11.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eConsider preventative medication; annual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAbigail\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7.35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnnual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eConsider preventative medication; continue annual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBronwen\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePrescribed preventative medication; annual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eContinue preventive medication; continue annual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFrances\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnnual screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eConsider preventative medication; continue annual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHannah\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3-yearly screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eConsider preventative medication; annual screening\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003e*mean 10-year (10Y) risk of the Tyrer-Cuzick (TC) and CanRisk (CR) models\u003c/em\u003e, \u003cb\u003eexcluding\u003c/b\u003e \u003cem\u003ea PRS and breast density (BD), **mean 10-year (10Y) risk of the Tyrer-Cuzick (TC) and CanRisk (CR models\u003c/em\u003e, \u003cb\u003eincluding\u003c/b\u003e \u003cem\u003ea PRS and breast density (BD).\u003c/em\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eReflexive thematic analysis\u003c/h2\u003e \u003cp\u003eFour themes were generated, \u003cem\u003e(i) possibility of change in risk never considered, (ii) a trusted source influences adapted risk appraisals, (iii) perceived value of new risk factor knowledge and (iv) heart versus head: changes in preventative management.\u003c/em\u003e After each pseudonymised quote a \u0026lsquo;D\u0026rsquo; or an \u0026lsquo;I\u0026rsquo; is used to indicate whether a decrease or an increase in risk was experienced.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003ePossibility of change in risk never considered\u003c/h2\u003e \u003cp\u003eOnly a minority of women had an awareness prior to receiving their updated breast cancer risk that certain risk factors (i.e. health behaviour/diet changes) could affect their estimated risks. Nevertheless, the majority did not seem to possess strong ideas as to whether risk could change, describing never consciously thinking about their risk changing:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cem\u003eNo, actually I probably didn\u0026rsquo;t think it would change, no, it didn\u0026rsquo;t really cross my mind that one, actually\u0026hellip; Abigail (I)\u003c/em\u003e \u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eMost women believed their risk would remain the same throughout their lifetime due to their family history, as they were not aware of any factors that would affect their risk as significantly. When approached by the clinic to receive a more precise risk estimate, it was only at this point where questions about whether risk could change were considered, with women describing feeling curious. Many acknowledged being motivated to seek a risk update due to the impact it could have on their children\u0026rsquo;s risk, whilst others expressed an interest in hearing about advances in the field. Although having no pre-conceived expectations as to whether their risk had changed, all women described wanting to receive an update in spite of the outcome or implications:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cem\u003e\u0026hellip;of course I want to know. I want to know whether it\u0026rsquo;s good or I want to know whether it\u0026rsquo;s bad. I need to know. So, there was no hesitation in my mind... Lisa (I)\u003c/em\u003e \u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eNotification of a risk reduction was described as shocking for some. For these women, shock appeared related to the strength of their family history, surprised that their risk could be reduced so dramatically with the inclusion of new risk factors. For Grace, receiving a negative genetic test challenged her expectations and beliefs about her risk, which she had held all her life:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cem\u003e\u0026hellip;I was expecting to be carrying the gene, and I was expecting to be told that I\u0026rsquo;m at high-risk, so I was quite shocked when I was told that I wasn\u0026rsquo;t, and I was low-risk, I wasn\u0026rsquo;t expecting that at all. Obviously, I was happy about it, but I wasn\u0026rsquo;t expecting it...Grace (D)\u003c/em\u003e \u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eAlthough initially finding a reduced risk a shock, women revealed feeling relieved, with Stef describing it as \u003cem\u003e\u0026lsquo;a weight lifted\u0026rsquo;\u003c/em\u003e. Conversely, those informed of an increase to their risk were disappointed, but not overly troubled by this news. This is potentially attributable to these women having always \u0026lsquo;lived\u0026rsquo; at increased risk of breast cancer, so although risk had increased, this knowledge did not appear to worry them significantly due to the support received from the clinic:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cem\u003eI kind of feel reassured and grateful that I know and that I've got this support system in place. But also it\u0026rsquo;s not, you know, it\u0026rsquo;s not great news is it, you know, but at least it\u0026rsquo;s in a context of support, you know [\u0026hellip;] I was one in four and I've gone to one in three, so it\u0026rsquo;s not a massively different risk. Hayley (I)\u003c/em\u003e \u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eJenny surmised that her risk could potentially change again, indicating her acceptance of the fluidity of risk estimation and her understanding that a clinically-derived breast cancer risk is not definitive:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cem\u003eIn two years' time they might come across something and say oh, we were wrong, your risk factor is virtually zero [\u0026hellip;] I think because I know that there could be change, I'm aware that my risk factors could change. Jenny (I)\u003c/em\u003e \u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eThis view was also discussed by others, who argued for regular updates if risk were to change frequently, especially if taking preventative medication or if new risk factors are discovered. Overall, however, women appeared to have little prior concern about their risk consultations and the potential for risk changing. This is likely attributable to women\u0026rsquo;s long lasting positive relationship with the clinic; identifying confidently that they would feel supported whatever the outcome.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eA trusted source influences adapted risk appraisal\u003c/h2\u003e \u003cp\u003eFrom their initial visit to the FHRPC all women recalled feeling protected by the service and grateful for annual screening. The clinic seemed to provide women with a sense of belonging and community, with consistency of staff, personalised care and a positive atmosphere being highly valued. Attending clinic annually became \u0026lsquo;\u003cem\u003eroutine\u003c/em\u003e\u0026rsquo; for some and looked forward to their annual engagement:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003e\u0026hellip;I really felt cared for and looked after and part of a family [at the FHRPC], because as I say, I\u0026rsquo;ve always trusted [name of clinician], the people I\u0026rsquo;ve met there, you know? I\u0026rsquo;ve always felt that they had my best interests at heart. Becky (D)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eWith this in mind, when receiving their updated breast cancer risk estimates women appeared positive and trusted the new estimate provided. Women\u0026rsquo;s trust in the service and the value attributed to it also seemed to influence the ease in which new risk estimates were internalised and accepted. Integration of new risk factors, breast density and a PRS seemed to be accomplished with relative ease, accepting the clinician\u0026rsquo;s knowledge and re-defining personal risk appraisals in line with this information:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cem\u003e\u0026hellip;the things that really stuck with me that we talked about were\u0026hellip;that I didn't have any of the genetic markers [high-penetrance genes], but they looked at 300 markers [SNPs] on my DNA, and that's where I had the higher risk, that\u0026rsquo;s where the higher risk came from. Harriet (I)\u003c/em\u003e \u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eThe majority of women described their risk as changed and attributed changes to breast density and a PRS, as well as results informing them of their non-carrier status for pathogenic variants in 12 high-penetrance breast cancer genes. Following communication of this information there appeared to be a shift in the majority of women\u0026rsquo;s understandings of their risk from their initial FHRPC visit, where a family history and the assumption of being a gene mutation carrier were considered the key drivers in their risk. Following their updated risk notification, women described appreciating the impact of these new risk factors, whilst also processing past assumptions about their genetic risk:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cem\u003eI had probably assumed and probably wrongly before I knew that there wasn\u0026rsquo;t a genetic link. What I hadn\u0026rsquo;t appreciated was some of the other factors still added up to the higher than average risk [\u0026hellip;] So again, let\u0026rsquo;s say I was surprised. I wasn\u0026rsquo;t particularly upset, but I was maybe surprised. But that\u0026rsquo;s always because I\u0026rsquo;d worked on an assumption...Bronwen (I)\u003c/em\u003e \u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eFollowing notification of their updated risk, women openly discussed understanding that low or high breast density, or, a low or high PRS resulted in risk reducing or increasing. Women described understanding the \u0026lsquo;take home message\u0026rsquo; of this information and felt they had sufficient knowledge to enable them to integrate this information into an improved understanding of risk:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cem\u003e\u0026hellip;he explained to me about how my breast density had changed since I started on the programme years ago and they\u0026rsquo;d become much more denser and now I was in the most dense category, and that obviously increased my risk...Alexa (I)\u003c/em\u003e \u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eDeveloping a \u0026lsquo;gist\u0026rsquo; understanding may have been facilitated by how both a PRS and breast density were communicated. Specifically, an analogy provided to explain a PRS/SNPs, as well as a visual representation of breast density was described as helpful in enabling women to understand the contribution of these factors to their updated risk. These techniques and positive relationships with the clinic appeared to result in \u003cem\u003emost\u003c/em\u003e personal risk appraisals being in line with the updated estimate provided.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003ePerceived value of new risk factor knowledge\u003c/h2\u003e \u003cp\u003eAll women mentioned breast density, a PRS and their non-carrier status for pathogenic variants when describing their change in risk. Non-carrier status for pathogenic variants in high-penetrance genes seemed to be particularly significant, with women elated by their result, not only for themselves but for their children. For some this information and a PRS was considered simultaneously. By doing so, attention attributed to their PRS appeared reduced, due to the overwhelming affective response associated with their non-carrier status. Instead, women appeared to possess a vague but mostly accurate understanding of their PRS and its contribution to their risk, and seemed satisfied with this level of knowledge. When considering the usefulness of knowing their PRS, some explained the futility of dwelling on the score, due to their inability to control it:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cem\u003eI can only manage the factors that I can manage [\u0026hellip;] The fact that they\u0026rsquo;re [SNPs] there, I can\u0026rsquo;t change them, so I\u0026rsquo;m not going to overly worry about it. Bronwen (I)\u003c/em\u003e \u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eBreast density results were considered in more depth. Prior to receiving their update, some women had a vague understanding of breast density, however most explanations comprised of inaccurate knowledge or misunderstandings. Accuracy of knowledge remained mixed after receiving an updated risk estimate. Women instead focused on the overall contribution of their breast density to their risk and as with knowledge for SNPs/a PRS, appeared satisfied with \u0026lsquo;gist\u0026rsquo; knowledge:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cem\u003eAs small as they are [her breasts], you know, they are made of matter that is not great in terms of breast cancer. You know, that\u0026rsquo;s how I read it, that\u0026rsquo;s how I feel about it...Lisa (I)\u003c/em\u003e \u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eMost women acknowledged the usefulness of knowing their breast density, with some considering or pursuing preventative medication to reduce it. Communication of breast density was also considered important more widely, with women advocating that all eligible woman should be given the opportunity to know their breast density. However, women identified some caveats to breast density communication. Specifically, they questioned the usefulness of breast density information if nothing conclusive can be done to manage it. Additionally, the usefulness of providing breast density information in isolation of other known risk factors was also considered.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eHeart versus head: changes in preventative management\u003c/h2\u003e \u003cp\u003eFor some women still under follow-up at the FHRPC, their updated risk estimates resulted in them being ineligible for annual screening. This was due to their risk reducing below the level recommended for additional screening in NICE guidelines. This appeared to cause conflict emotionally, with women understanding they were no longer eligible and accepting this, yet feeling a sense of loss from being discharged. Despite being pleased that risk had reduced, losing the protectiveness and comfort the service offers was challenging to reconcile:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003e\u0026hellip;when he said I\u0026rsquo;d go to the three [yearly screening], that\u0026rsquo;s just the bit that made me think a bit. And I\u0026rsquo;ve not got to think like that but it\u0026rsquo;s just made me think, oh, crikey, yeah, a bit, makes me a bit more nervous now of it [breast cancer] again, but then I shouldn\u0026rsquo;t do, I\u0026rsquo;ve got to think of the positives. Leanne (D)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eSome appeared dubious about population screening and attending 3-yearly. Although trusting their updated risk and the clinician\u0026rsquo;s recommendations to attend for 3-yearly screening, women were apprehensive about the level of service they would encounter, as well as whether staff would be aware of their FHRPC involvement. For these women, 3-yearly screening would be a difficult transition despite understanding why they were no longer eligible. These concerns aligned with those who had previously been discharged from the clinic at age 60, who criticised population screening for being impersonal, with some not trusting negative mammogram results:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cem\u003eI\u0026rsquo;m just going to be a number to them whereas I\u0026rsquo;m a name to [name of clinician] [\u0026hellip;] I walk into the one there and they don\u0026rsquo;t know my name, they don\u0026rsquo;t know me from Adam or Eve, they take longer to get the results back to you. It\u0026rsquo;s only every three years. Nobody ever discusses anything with you [\u0026hellip;] there\u0026rsquo;s no connection. Becky (D)\u003c/em\u003e \u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eIn contrast, women in follow-up notified of a risk increase described experiencing a sense of relief due to remaining eligible for annual screening. Additionally, those who had been discharged and notified that their updated risk entitled them to receive annual screening were elated to be back in the FHRPC. For these women an increased risk was of course concerning, but this update seemed to act as an \u0026lsquo;entrance ticket\u0026rsquo; or gateway back into the FHRPC. These women appeared to focus more on the positivity of additional surveillance, rather than the implications of the risk itself:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cem\u003eIt\u0026rsquo;s a double-edged sword, isn\u0026rsquo;t it? Your risk has gone higher, but guess what, you\u0026rsquo;re going to have it [mammography] once a year, yay. No, I\u0026rsquo;m actually quite happy about that, and I\u0026rsquo;m relieved, because if my risk level has gone up, obviously I then want as much preventative help, if you like, as possible, so I\u0026rsquo;m well happy to come once a year\u0026hellip;Paula (I)\u003c/em\u003e \u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eThree women at the time of interviewing were taking preventative medication, with one woman, Leanne, advised to discontinue as a result of her updated risk. Leanne described feeling encouraged that taking preventative medication had appeared to reduce her risk and was positive about the prospect of being able to take a natural form of HRT to reduce her menopausal symptoms. Other women considered the thought of being asked to discontinue preventative medication hypothetically, with many explaining that although potentially worrying, medication was prescribed with the correct knowledge available at the time and not due to inaccurate information or medical negligence. Other women who had been offered preventative medication described it as \u003cem\u003e\u0026lsquo;a no brainer\u0026rsquo; (Hayley, I)\u003c/em\u003e if it reduces risk but were cautious about side-effects, describing trusting the advice of the clinician but also needing to weigh up the ratio of harms to benefits before use.\u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eWomen who experienced a change in their clinically-derived breast cancer risk estimate reacted positively and trusted the estimate provided. A reduction in risk was met with relief as well as surprise, due to the previously perceived impact of family history on risk compared to other risk factors. Those who experienced a risk increase were not overly concerned by this, possibly due to seeing themselves as being at increased risk for most of their lives. Women described having a longstanding positive relationship with the FHRPC which appeared to influence the trust they had in their updated risk, as well as influencing the apparent ease at which they were able to integrate new risk information into pre-existing risk appraisals. A \u0026lsquo;gist\u0026rsquo; understanding of new risk information seemed to be sufficient in enabling women to understand the \u0026lsquo;take home message\u0026rsquo; of their breast cancer risk. Finally, for those at increases risk, updated estimates enable those under follow-up to remain so and facilitated a pathway back into the service for those previously discharged, resulting in positive reactions to this risk level. However, ineligibility for continued annual screening for those at reduced risk was difficult to reconcile.\u003c/p\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eRelevance to existing literature\u003c/h2\u003e \u003cp\u003eWomen who were informed that their risk had increased accepted this news and did not appear overly concerned, nor did those referred back into the clinic blame the service for being discharged previously. Instead women here focused on their eligibility for annual screening and the elation of being referred back into the clinic. This contrasts with research suggesting that those given information about an increased risk or negative health outcome question the accuracy of the results and credibility of the source [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. It is widely established that in the UK, cancer screening is highly valued [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. Specifically, women living at chronic risk of breast and ovarian cancer view frequent screening as providing peace of mind and a sense of control [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. Additionally, prior to diagnosis, those with breast cancer recalled having confidence in mammography, the clinic and their care [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. In the present study the positivity of qualifying for more frequent screening outweighed the implications of a change in risk. This is in line with research that suggests although clinical risk consultations may contain messages of uncertainty and notifications of an increased risk, women tend to focus on the reassurance of the appointment and being a part of a \u0026lsquo;surveillance\u0026rsquo; society [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eWomen\u0026rsquo;s appraisals of their breast cancer risk following their update were mostly in line with the clinical estimate provided. Women were able, with confidence, to attribute risk changes to their personal breast density, PRS or a combination, acknowledging the implications of these new risk factors. These findings are in contrast to those found with women from the general screening population who also received similar feedback where some women did not identify with their risk estimates, nor did they draw on specific risk factors to explain their risk [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. However, there were significant differences in how risk was communicated in these two studies. For women in the general population, notification was received via letter, with a minority attending a consultation. Instead, established relationships with the clinic in the present study, as well as the \u003cem\u003e\u0026lsquo;routine\u0026rsquo;\u003c/em\u003e of discussing breast cancer risk may have influenced how open women were to receiving new risk information. This positive relationship with the FHRPC also seemed to positively impact women\u0026rsquo;s trust in the updated risk estimate provided, as well as influencing views on its credibility. It may also account for why those discharged felt apprehensive when faced with population screening, as relationships built at the FHRPC and comfort received would cease. This apprehension is also found in women offered risk estimation and stratification in the general population, with those previously receiving annual screening questioning the safety of 3-yearly screening and feeling less in control of their risk [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eImplications for practice\u003c/h2\u003e \u003cp\u003eWomen who were informed that their updated breast cancer risk estimate caused them to be ineligible for additional breast screening felt a sense of loss and were wary about population screening. In FHRPCs communication needs to be carefully managed when women are discharged, with reasons thoroughly explained and concerns surrounding the perceived competence of population breast screening alleviated. Specifically, FHRPCs should reinforce that staff (i.e. radiographers and radiologists) at population screening require the same level of training as those performing mammograms at FHRPCs. At population screening, radiographers should be made aware of women\u0026rsquo;s involvement in FHRPCs. Possessing this knowledge and demonstrating this to those recently discharged would perhaps reduce apprehensions and create a more personalised environment, making this transition easier.\u003c/p\u003e \u003cp\u003eIt is understood that \u0026lsquo;gist\u0026rsquo; health messages can increase patient satisfaction and are important for facilitating understanding and informed decision making around health risks [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. Understanding the \u0026lsquo;gist\u0026rsquo; of their updated risk was sufficient for women to appreciate the most salient information from their consultations, resulting in mostly accurate risk appraisals and an appreciation of the impact of new risk factors. It has been recommended that risk communication research should move away from assessing patient\u0026rsquo;s verbatim representations of risk information and instead assess \u003cem\u003e\u0026lsquo;gist\u0026rsquo;\u003c/em\u003e representations, asking the question, \u003cem\u003e\u0026lsquo;what does this risk information mean to the individual?\u003c/em\u003e\u0026rsquo; [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. In clinical settings this level of understanding should be facilitated to enable patients to gain sufficient knowledge to inform \u0026lsquo;accurate\u0026rsquo; personal appraisals of their risk and aid informed decision making. The use of visuals (e.g. breast density images) and analogies (e.g. like that given to explain SNPs/a PRS in the present study; see supplementary file) appear to be an effective way of facilitating this [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eWomen in the present study advocated for breast density notification for all. In the UK notification of personal breast density is only provided in research settings. Research from the US advises that education materials and breast density communication in clinical settings needs to be specifically addressed in order to help women make informed decisions about prevention management [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. Measures of breast density need to be agreed upon and prevention advice clear in the UK before communicating at a population level [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. In the present study a PRS/SNPs information was attended to less than breast density, with a negative pathogenic variant test for high penetrance genes overshadowing the implications of a PRS. Healthcare professionals should consider providing written summaries of the implications of a PRS, or direct patients to a website to help facilitate knowledge acquisition once the affective response of receiving negative genetic test results subsides.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eStrengths and limitations\u003c/h2\u003e \u003cp\u003eThis is the first research study for any disease type to explore how a change in personal risk is understood, and reacted to in a clinical setting. It is important however to be cognisant that women interviewed were predominantly White-British, from one FHRPC and were seen by the same clinician employed at the clinic for the duration of women\u0026rsquo;s involvement with the service. Therefore, the relationship these women have with the clinic, which has been described as a \u0026lsquo;centre for excellence\u0026rsquo;, may not be representative of patient-clinician relationships in other FHRPCs or clinical settings worldwide, although it clearly shows that it is possible for patients to receive revised risk estimates without major adverse reactions.\u003c/p\u003e \u003cp\u003eFindings in qualitative data analysis are at least partly a result of the subjectivity of the researchers generating and analysing the data [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. The research team contributing to this work are from a range of disciplinary backgrounds, including health psychology, medical oncology and clinical genetics. The multi-disciplinary nature of this team resulted in meaningful discussions about the data, providing different perspectives on the themes generated. Prior to data generation, the research team had pre-existing apprehensions regarding reactions to a change in risk, especially if related to a change in preventative management. Although these concerns did not materialise, pre-conceived ideas were discussed openly prior to the interviews.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eFurther research\u003c/h2\u003e \u003cp\u003eFuture research should establish how relationships between patients and doctors impact the effectiveness of risk communication and the trust patients have in updated risk estimates across different disease types and clinical settings. As well, research aiming to assess breast cancer risk appraisals across the entire FH-Risk cohort would be beneficial. This would facilitate an understanding as to whether risk appraisals are in line with the clinical estimates provided overall, as well as enable opportunities to explore how women view a changes in risk, as well as whether they have an understanding of the contributing risk factors. The longevity of \u0026lsquo;gist\u0026rsquo; understandings and the impact this has on patient\u0026rsquo;s appraisals of a given disease risk and their informed decision making about prevention should also be assessed.\u003c/p\u003e \u003c/div\u003e"},{"header":"Conclusion","content":"\u003cp\u003eWomen were positive about receiving a notification of change in breast cancer risk and trusted the estimate provided. This may have been due to a strong trust in the service communicating these updated risk estimates, facilitating an accurate appraisal of risk which was mostly in line with the clinical estimate provided.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eFH-Risk \u0026ndash; Family history risk study\u003c/p\u003e\n\u003cp\u003eFHRPC \u0026ndash; Family history risk and prevention clinic\u003c/p\u003e\n\u003cp\u003eHRT \u0026ndash; Hormone replacement therapy\u003c/p\u003e\n\u003cp\u003eNICE \u0026ndash; National institute for health and care excellence\u003c/p\u003e\n\u003cp\u003ePPIE \u0026ndash; Patient and public involvement and engagement\u003c/p\u003e\n\u003cp\u003ePRS \u0026ndash; Polygenic risk score\u003c/p\u003e\n\u003cp\u003eSNPs \u0026ndash; Single nucleotide polymorphisms\u0026nbsp;\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEthical approval was granted by HSC REC A ethics committee (ref: 21/NI/0130). All women provided verbal informed consent that was audio-recorded.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConsent to publish anonymised data, including direct quotes was obtained from all the women who took part in the present study. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated during and/or analysed during the current study are not publicly available as they may contain information that would compromise participant consent, but are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no conflict of interest. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe original FH-Risk study was funded by an NIHR Programme Grant for Applied Research (RP-PG-0707-10031). The present work was supported by a Medical Research Council PhD studentship for the primary author (MR/N013751/1). This work was also supported by the NIHR Manchester Biomedical Research Centre Cancer Prevention and Early Detection theme (IS-BRC-1215-20007 and NIHR203308). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. These funding sources had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe concept of the study was designed by all authors. Recruitment was carried out by VGW and LF. Data were collected by VGW. Primary data analysis was conducted by VGW and supervised by DPF. VGW wrote the manuscript. The final manuscript was reviewed, edited and approved by all the authors.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe would like to acknowledge the wider team at the FHRPC, as well as those in the research office. We would also like to thank the Patient and Public Involvement Group as well as those at VOCAL who helped develop the topic guide for this study. Finally, we would like to extend a special thanks to all the women who took part for their continued dedication to the FH-Risk studies.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eNational Institute of Health and Clinical Excellence. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. NICE clinical guideline 164., 2013; 2019.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111\u0026ndash;30.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTyrer-Cuzick (IBIS). Risk Evaluation Tool, Version 8. Retrieved from \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://ems-trials.org/riskevaluator/\u003c/span\u003e\u003cspan address=\"https://ems-trials.org/riskevaluator/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (accessed June 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCarver, T., Hartley, S., Lee, A., Cunningham, A. P., Archer, S., Babb de Villiers,C., \u0026hellip; Antoniou, A. C. (2021). CanRisk Tool\u0026mdash;A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants.Cancer Epidemiology, Biomarkers \u0026amp; Prevention, 30(3), 469\u0026ndash;473.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrentnall AR, Cohn WF, Knaus WA, Yaffe MJ, Cuzick J, Harvey JA. A case-control study to add volumetric or clinical mammographic density into the Tyrer-Cuzick breast cancer risk model. J breast imaging. 2019;1(2):99\u0026ndash;106.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrentnall, A. R., van Veen, E. M., Harkness, E. F., Rafiq, S., Byers, H., Astley,S. M., \u0026hellip; Evans, D. G. R. (2020). A case\u0026ndash;control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. International journal of cancer, 146(8), 2122\u0026ndash;2129.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEvans, D. G. R., van Veen, E. M., Harkness, E. F., Brentnall, A. R., Astley, S. M.,Byers, H., \u0026hellip; Howell, A. (2022). Breast cancer risk stratification in women of screening age: incremental effects of adding mammographic density, polygenic risk, and a gene panel. Genetics in Medicine, 24(7), 1485\u0026ndash;1494.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee, A., Mavaddat, N., Wilcox, A. N., Cunningham, A. P., Carver, T., Hartley, S.,\u0026hellip; Antoniou, A. C. (2019). BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genetics in Medicine, 21(8),1708\u0026ndash;1718.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePal Choudhury, P., Brook, M. N., Hurson, A. N., Lee, A., Mulder, C. V., Coulson, P.,\u0026hellip; Garcia-Closas, M. (2021). Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. Breast Cancer Research, 23, 1\u0026ndash;5.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFicorella, L., Eriksson, M., Czene, K., Leslie, G., Yang, X., Carver, T. J., \u0026hellip; Antoniou,A. C. (2023). Incorporating continuous mammographic density into the BOADICEA breast cancer risk prediction model. Cancer Research, 83(7_Supplement), 4174\u0026ndash;4174.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHowell, A., Gandhi, A., Howell, S., Wilson, M., Maxwell, A., Astley, S., \u0026hellip; Evans,D. G. (2020). Long-term evaluation of women referred to a breast cancer family history clinic (Manchester UK 1987\u0026ndash;2020). Cancers, 12(12), 3697.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWoof VG, Howell A, McWilliams L, Evans DG, French DP. (2022). How do women who are informed that they are at increased risk of breast cancer appraise their risk? A systematic review of qualitative research. Br J Cancer, 1\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWoof VG, McWilliams L, Howell A, Evans DG, French DP. How do women at increased risk of breast cancer make sense of their risk? An interpretative phenomenological analysis. Br J Health Psychol. 2023;00:1\u0026ndash;16.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEvans, D. G., Brentnall, A., Byers, H., Harkness, E., Stavrinos, P., Howell, A., \u0026hellip;FH-risk study Group. (2017). The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case\u0026ndash;control study. Journal of medical genetics, 54(2), 111\u0026ndash;113.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEvans, D. G., Astley, S., Stavrinos, P., Harkness, E., Donnelly, L. S., Dawe, S.,\u0026hellip; Howell, A. (2016). Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics:a dual cohort study. NIHR Journals Library, Southampton (UK); PMID: 27559559.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMavaddat, N., Michailidou, K., Dennis, J., Lush, M., Fachal, L., Lee, A., \u0026hellip; MacInnis,R. J. (2019). Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. The American Journal of Human Genetics, 104(1), 21\u0026ndash;34.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBalleyguier C, Ayadi S, Van Nguyen K, Vanel D, Dromain C, Sigal R. BIRADS\u0026trade; classification in mammography. Eur J Radiol. 2007;61(2):192\u0026ndash;4.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBreast Cancer Association Consortium. Breast cancer risk genes\u0026mdash;association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428\u0026ndash;39.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eO\u0026rsquo;reilly M, Parker N. Unsatisfactory Saturation\u0026rsquo;: a critical exploration of the notion of saturated sample sizes in qualitative research. Qualitative Res. 2013;13(2):190\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBraun V, Clarke V. Reflecting on reflexive thematic analysis. Qualitative Res sport Exerc health. 2019;11(4):589\u0026ndash;97.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMinistry of Housing, Communities, Local Government. English indices of deprivation 2019. [Online] 2019 [Accessed 1st September 2023]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.gov.uk/government/statistics/english-indices-of-deprivation-2019\u003c/span\u003e\u003cspan address=\"https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePanzer M, Renner B. To be or not to be at risk: Spontaneous reactions to risk information. Psychol Health. 2008;23(5):617\u0026ndash;27.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWaller J, Osborne K, Wardle J. Enthusiasm for cancer screening in Great Britain: a general population survey. Br J Cancer. 2015;112(3):562\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKenen R, Ardern-Jones A, Eeles R. Living with chronic risk: healthy women with a family history of breast/ovarian cancer. Health Risk \u0026amp; Society. 2003;5(3):315\u0026ndash;31.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClements, A., Henderson, B. J., Tyndel, S., Evans, G., Brain, K., Austoker, J., \u0026hellip;PIMMS Study Management Group. (2008). Diagnosed with breast cancer while on a family history screening programme: an exploratory qualitative study. European journal of cancer care, 17(3), 245\u0026ndash;252.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eParsons EP, Beale V, Bennett H, Jones J, Lycett EJ. Reassurance through surveillance in the face of clinical uncertainty: the experience of women at risk of familial breast cancer. Health Expect. 2000;3(4):263\u0026ndash;73.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcWilliams L, Ruane H, Ulph F, Woof VG, Harrison F, Evans DG, French DP. (2023). What do women think about having received their breast cancer risk as part of a risk-stratified NHS Breast Screening Programme? A qualitative study. Br J Cancer, 1\u0026ndash;10.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eReyna VF. A theory of medical decision making and health: fuzzy trace theory. Med Decis Making. 2008;28(6):850\u0026ndash;65.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBlalock SJ, DeVellis RF, Chewning B, Sleath BL, Reyna VF. Gist and verbatim communication concerning medication risks/benefits. Patient Educ Couns. 2016;99(6):988\u0026ndash;94.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWilhelms EA, Reyna VF. Effective ways to communicate risk and benefit. The virtual mentor: VM. 2013;15(1):34.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchifferdecker, K. E., Tosteson, A. N., Kaplan, C., Kerlikowske, K., Buist, D. S.,Henderson, L. M., \u0026hellip; Wernli, K. J. (2020). Knowledge and perception of breast density,screening mammography, and supplemental screening: in search of \u0026ldquo;informed\u0026rdquo;. Journal of general internal medicine, 35, 1654\u0026ndash;1660.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDuffy, S. W., Morrish, O. W., Allgood, P. C., Black, R., Gillan, M. G., Willsher,P., \u0026hellip; Maroni, R. (2018). Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer. European Journal of Cancer, 88, 48\u0026ndash;56.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcan","sideBox":"Learn more about [BMC Cancer](http://bmccancer.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bcan/default.aspx","title":"BMC Cancer","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Breast cancer, breast cancer risk, cancer prevention, early detection, updated risk estimates, qualitative","lastPublishedDoi":"10.21203/rs.3.rs-3643438/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3643438/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eIntroducing breast density and polygenic risk scores into breast cancer prediction models results in greater precision and can involve alterations to previously communicated risk estimates and preventative management. This study explored how women from a UK family history risk and prevention clinic view, experience and understand a change in communicated risk.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eTwenty-two women were interviewed; 11 received an increased risk and 11 a decreased risk. Data were analysed using reflexive thematic analysis.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eFour themes were generated: \u003cem\u003e(i) possibility of change in risk never considered\u003c/em\u003e, illustrating women believed their risk estimates would remain unaltered due to their family history, hence receiving a lower risk was shocking but a relief, but an increased risk somewhat unsurprising, \u003cem\u003e(ii) a trusted source influences adapted risk appraisals\u003c/em\u003e, highlighting the clinic\u0026rsquo;s reputation as an information source, as well as personal connections with the service effecting risk appraisals, \u003cem\u003e(iii) perceived value of new risk factor knowledge\u003c/em\u003e, where women contemplated the usefulness of knowing their breast density and polygenic risk scores, \u003cem\u003e(iv) heart versus head: changes in preventative management\u003c/em\u003e, where the implications of an updated risk estimate was processed.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e \u003cp\u003eWomen reacted positively to their updated breast cancer risk estimates and trusted the information provided, even when preventative management options changed.\u003c/p\u003e","manuscriptTitle":"How do women experience a change in their clinically-derived breast cancer risk estimates: views from a UK Family History Risk and Prevention Clinic","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-08-02 18:05:53","doi":"10.21203/rs.3.rs-3643438/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-10-23T11:20:45+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-09-07T17:19:34+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-09-06T23:30:02+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"77982834521251916293596015096986148330","date":"2024-08-28T05:25:29+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"223656380955611963048758502147269076633","date":"2024-08-28T04:32:05+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2023-12-11T09:35:11+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2023-12-11T08:52:56+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2023-11-30T11:44:43+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2023-11-30T08:05:26+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Cancer","date":"2023-11-21T10:09:52+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcan","sideBox":"Learn more about [BMC Cancer](http://bmccancer.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bcan/default.aspx","title":"BMC Cancer","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"9af5d881-521d-4451-b8f7-561890da9f7c","owner":[],"postedDate":"August 2nd, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2026-02-02T16:09:21+00:00","versionOfRecord":{"articleIdentity":"rs-3643438","link":"https://doi.org/10.1186/s12885-026-15651-w","journal":{"identity":"bmc-cancer","isVorOnly":false,"title":"BMC Cancer"},"publishedOn":"2026-01-29 15:59:22","publishedOnDateReadable":"January 29th, 2026"},"versionCreatedAt":"2024-08-02 18:05:53","video":"","vorDoi":"10.1186/s12885-026-15651-w","vorDoiUrl":"https://doi.org/10.1186/s12885-026-15651-w","workflowStages":[]},"version":"v1","identity":"rs-3643438","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3643438","identity":"rs-3643438","version":["v1"]},"buildId":"zQwnuV7TCBrMSSSToR1PI","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}